Moderna, Inc. (MRNA) Q2 2020 Earnings Results

Moderna Misses on EPS, Stock Down 3.39%

Moderna's earnings report shows a loss per share that was slightly better than expected, but the lack of revenue data and guidance contributed to a stock decline of 3.39%. Investors may be concerned about the company's future performance, especially given the current market challenges. The focus on mRNA technology remains a key point for the company's strategy moving forward.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.31	N/A	+13.89%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious outlook, emphasizing their focus on mRNA technology. They acknowledged the challenges in the current market environment.

We are focused on advancing our mRNA technology platform.

Current market conditions are challenging, but we remain committed to our pipeline.

Moderna Misses on EPS, Stock Down 3.39%

Key numbers

Management commentary

Moderna, Inc.

More earnings this week

Moderna Misses on EPS, Stock Down 3.39%

Key numbers

Management commentary